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EQ-5D-5L versus 3L: the impact on cost-effectiveness in 
the UK. 
 
 
 
  
ABSTRACT 250 words (250 words max) 
Objectives 
To model the relationship between EQ-5D-3L and EQ-5D-5L and examine how differences impact on cost-
effectiveness in case studies. 
Methods 
We used two datasets that included 3L and 5Lfrom the same respondents. The EuroQoL dataset (n=3551) 
included patients with different diseases and a healthy cohort. The National Data Bank (NDB) dataset included 
patients with rheumatoid disease (n=5205). We estimated a system of ordinal regressions in each dataset using 
copula models, to link responses to the 3L instrument to 5L and its UK tariff, and vice versa. Results were 
applied to nine cost-effectiveness studies.  
Results 
Best-fitting models differed between EuroQoL and NDB datasets in terms of the explanatory variables, copulas 
and coefficients. In both cases the coefficients of the covariates and latent factor between 3L and 5L were 
significantly different, indicating that moving between instruments is not simply a uniform realignment of the 
response levels for most dimensions. In the case studies, moving from 3L to 5L caused a decrease of up to 87% 
in incremental QALYs gained from effective technologies in almost all cases. ICERs increased, often 
substantially. Conversely, one technology with a significant mortality gain saw increased incremental QALYs.  
Conclusion 
5L shifts mean utility scores up the utility scale towards full health and compresses them into a smaller range, 
compared to 3L. Improvements in quality of life are valued less using 5L than with 3L. 
3L and 5L can produce substantially different estimates of cost effectiveness. There is no simple proportional 
adjustment that can be made to reconcile these differences.  
 
 
  
INTRODUCTION 
The EQ-5D comprises a descriptive system of health-UHODWHGTXDOLW\RIOLIHDQGDVVRFLDWHGWDULIIVRU³XWLOLW\´
scores. The descriptive system covers five dimensions of health: mobility, ability to self-care, ability to 
undertake usual activities, pain and discomfort, and anxiety and depression. The original version of EQ-5D 
allows respondents to indicate the degree of impairment on each dimension according to three levels (no 
problems, some problems, extreme problems). This is the EQ-5D-3L. A new version of the instrument, EQ-5D-
5L, includes five levels of severity for each dimension (no problems, slight problems, moderate problems, 
severe problems, and extreme problems) ZLWKWKHLQWHQWLRQRILPSURYLQJWKHLQVWUXPHQW¶VVHQVLWLYLW\DQG
reducing ceiling effects1. Tariffs are anchored around 1 for full health and 0 for states considered equivalent to 
death, based on estimates from samples of the general population. For the 3L, these tariffs were based on a 
Time-Trade-Off (TTO) valuation method. In the UK, these tariffs range from 1 for full health to -0.594. 35% 
(84/ 243) of the health states are valued with a negative score. There is a gap between full health and the next 
level of impairment valued at 0.883. Tariffs for the 5L version are now available for England2, Canada3, Japan4, 
Uruguay5, the Netherlands6 and Korea7. 7KHYDOXDWLRQPHWKRGVXVHGIRU/XVHGDFRPELQDWLRQRIXSGDWHG³OHDG
WLPH´772PHWKRGVDQG'LVFUHWH&KRLFH([SHULPHQWV'&(8. In England, this has led to a smaller range of 
values (from 1 to -0.281), a smaller gap at the upper end of the distribution (0.951 is the next score after 1) and 
fewer values below 0 (5%, 153/3125).  
 
EQ-5D is one of the most widely used instruments underpinning economic evaluations conducted in terms of 
cost-per Quality Adjusted Life Year (QALY), calculated from the tariff scores. It is therefore essential to 
understand the implications of using the new 5L version of the instrument compared to the 3L version. This 
paper provides information on how the two versions of EQ-5D relate to each other, using the UK/English tariffs. 
It should be noted that this 5L tariff could be subject to change as it progresses through the peer review process. 
We use two datasets where respondents filled in both 3L and 5L instruments. We estimate the joint distribution 
of responses to the two instruments. This model is then used in 9 cost-effectiveness studies to compare results 
when using directly observed 3L values with estimated 5L results.  
 
METHODS 
Data 
We used two datasets.  
 The first was provided by the EuroQoL group (the EQG data). Between August 2009 and September 2010, the 
EuroQoL Group coordinated and partly funded a data collection study. Its main aim was to collect data on both 
versions of EQ-5D, the 3L and 5L, to compare them in terms of their measurement properties and to generate an 
interim value set for 5L using a mapping (or cross-walk) approach. The questionnaire introduced the 5 level 
version of EQ-5D first, followed by a few background questions (age, gender, education, etc), then the 3 level 
version of EQ-5D, the EQ-5D visual analogue scale, a set of five dimension specific rating scales and finally the 
WHO (five) Well-Being index. The study was carried out in 6 countries: Denmark, England, Italy, the 
Netherlands, Poland and Scotland and included eight broad patient groups (cardiovascular disease, respiratory 
disease, depression, diabetes, liver disease, personality disorders, arthritis, and stroke) and a student cohort 
(healthy population). Each country used the official EQ-5D language versions and data was mainly collected 
through specialist hospitals/centres and patient recruitment agencies. All countries used paper and pencil 
questionnaires, apart from England which used an online version. In all countries, except Italy, sampling 
methods ensured a wide range of severity across all the 5L and 3L dimensions. 
 
The National Data Bank (NDB) for Rheumatic Diseases is a register of patients with rheumatoid disease, 
primarily recruited by referral from US and Canadian rheumatologists. Information supplied by participants is 
validated by direct reference to records held by hospitals and physicians (A minority of cases come by self-
referral, with medical details obtained by NDB in the same way). Full details of the recruitment process are 
given by Wolfe and Michaud (2011)9 . The EQ-5D responses and other patient-supplied data are collected by 
various means, primarily postal and web-based questionnaires completed directly by patients. Data collection 
began in 1998 and continues to the present, in waves administered in January and July of each year. In 2011, 
there was a switch from 3-level to the 5-level version of EQ-5D and both versions were included in the January 
2011 wave. The NDB questionnaire is 27 pages long and it includes many general as well as RA specific 
questions. 5L and 3L are on pages 11 and 22 of the questionnaire respectively. This wave is used to estimate the 
model. 
 
Statistical analysis 
The aim is to estimate the relationship between the two instruments. Hernandez and Pudney have previously 
developed a flexible model which allows analysis of the joint responses to 3L and 5L10. Full details are provided 
there. Responses to 3L and 5L are ordinal. The model reflects this in a system of 10 ordinal regressions, each of 
which is used to estimate the response level for one of the two versions of EQ-5D conditional on covariates (age 
and gender), arranged into the five health domains. The model reflects any tendency for an individual to give 
more or less positive responses across domains via a latent factor representing background response behaviour.   
A copula approach is used to specify the bivariate distribution of each 3L, 5L pair of responses. This captures 
the strong association between 3L and 5L responses within each health domain, without necessarily assuming 
that the strength of the association is the same in all parts of the health distribution ± for example, someone who 
has experienced extreme pain may answer the pain questions in a more focused and coherent way than someone 
without experience of chronic pain. Five different copulas were examined (Gaussian, Clayton, Frank, Gumbel 
and Joe) which reflect different types and strengths of dependence at different parts of the distribution, with the 
data informing the most appropriate final choice of copula.   
 
 
 
 
Statistical models like this are sensitive to the distributional assumptions, the usual one being normality. 
Misspecification of the joint residual distribution may lead to significant bias in the estimated coefficients of the 
covariates, in addition to giving a distorted picture of the dependence. For this reason, mixture distributions are 
used to allow for non-normality in the residuals and the lateQWIDFWRUUHSUHVHQWLQJWKHLQGLYLGXDO¶VUHVSRQVH
behaviour. 
 
 
Cost effectiveness case studies 
We used the copula mapping models in nine cost-effectiveness case studies.  
 
All were economic evaluations based on individual patient level data using 3L. We made a pragmatic decision 
in selecting case-studies. We sought collaborators who had previously completed suitable studies using the 3L 
instrument and who were willing and able to replicate their study substituting predicted utility scores for 5L 
using a bespoke Stata command.  Included studies were: 
1) CARDERA - The Combination of Anti-Rheumatic Drugs in Early Rheumatoid Arthritis (CARDERA) 
trial was a double-blind, factorial designed, placebo-controlled randomized trial which compared the 
benefits of adding cyclosporine, high-dose step-down prednisolone or both to methotrexate 
monotherapy11. 3L was administered to patients at baseline, 6, 12, 18 and 24 months12.  
2) CACTUS - The Cost-effectiveness of Aphasia Computer Treatment Compared to Usual Stimulation 
(CACTUS) pilot randomized controlled trial tested the feasibility of comparing self-managed computer 
therapy combined with usual stimulation (such as participation in normal language stimulation 
activities and support groups) to usual stimulation alone in people with aphasia13. 3L was completed at 
baseline, 3 and 8 months.  
3) RAIN - The Risk Adjustment in Neurocritical care (RAIN) trial compared a) Management in a 
dedicated QHXURFULWLFDOFDUHXQLWYHUVXVDFRPELQHGQHXURJHQHUDOFULWLFDOFDUHXQLWDQGEµ(DUO\¶
WUDQVIHUWRDQHXURVFLHQFHFHQWUHYHUVXVµQRRUODWH¶WUDQVIHUIRUSDWLHQWVZKRLQLWLDOO\SUHVHQWDWDQRQ-
neuroscience centre and do not require urgent neurosurgery, for patients with acute traumatic brain 
injury. 3L was completed at 3 months.  
4) IMPROVE - The Immediate Management of Patients with Rupture: Open Versus Endovascular Repair 
(IMPROVE) trial compared either endovascular repair or open repair of ruptured abdominal aortic 
aneurysm (AAA)14. 3L was administered at 3 and 12 months.  
5) COUGAR-02 - The COUGAR-02 randomised, controlled, open-labelled trial compared docetaxel 
chemotherapy plus active symptom control and active symptom control only in patients in the UK with 
advanced adenocarcinoma of the oesophagus, oesophagogastric junction, or stomach15 . Patients 
completed the EQ-5D at baseline, during clinic visits at weeks 3, 6, 9 and 12, then every 6 weeks for up 
to 1 year and then every 3 months until death. 
6) ARCTIC - The Attenuated dose Rituximab with ChemoTherapy in CLL (ARCTIC) study was a multi-
centre, randomised, controlled, open, phase IIB non-inferiority trial conducted in previously untreated 
patients with Chronic Lymphocytic Leukaemia (CLL)16,17. It compared fludarabine, cyclophosphamide 
and rituximab (FCR), which is considered conventional frontline therapy, with fludarabine, 
cyclophosphamide, mitoxantrone and low dose rituximab (FCM-miniR). 3L was completed at baseline, 
after 3 cycles of therapy, at the end of therapy, 3 months after the end of therapy and then every 3 
months after the end of therapy until 24 months post randomisation (i.e. at 6, 9, 12, 18 and 24 months 
post randomisation). 
7) SHARPISH - The Self-Help and Relapse Prevention in Smoking for Health (SHARPISH) trial18 sought 
to estimate the effectiveness and cost-effectiveness of self-help booklets versus a single leaflet to 
prevent smoking relapse in people who had stopped smoking for four weeks. 3L was administered at 
baseline, 2 months and 11 months post-randomisation. 
8) WRAP ± the Weight-Reduction Activity Programme (WRAP)19 was a multi-centre, non-blinded, three-
arm parallel groups randomised controlled trial of two commercial weight loss programmes, compared 
to a brief intervention in overweight adults. 3L was administered at baseline, 3, 12 and 24 months. 
9) CvLPRIT - The CvLPRIT (Complete- compared to Lesion-Only Revascularisation For Myocardial 
Infarction) trial20 randomised patients presenting with ST-segment elevation Myocardial Infarction 
(STEMI) with bystander stenosis to an infarct-only strategy (only treat the blocked artery which caused 
the heart attack) vs. complete revascularisation (treat the blocked artery and also treat any narrowed 
arteries which may cause heart attacks in future). 3L was administered immediately before discharge 
and at 12 months post-discharge. 
 
We use the UK value sets for the 3L and the English value set for the 5L21,22. 
RESULTS 
Datasets  
After exclusion of missing values, there were final estimation samples of 3551 and 5205 respondents in the 
EQG and NDB datasets respectively. The EQG sample is younger and contains more males than the NDB (see 
Table 1). 
 
Figure 1 shows histograms of the response distributions for each dimension of the 3L and 5L versions of EQ-5D 
in both datasets. There are differences both across the dimensions and between the datasets. Four distinct 
distributional shapes can be identified: 
i. Decreasing profile with a dominant mode at the first category. 
This distributional shape can be seen in the self-care dimension of both 3L and 5L and in the mobility and usual 
activities dimension of 5L in the EQG dataset and on the self-care and anxiety/depression of both versions of 
EQ-5D in the NDB dataset. 
ii. Decreasing profile with a heavier central section. 
In the EQG dataset, the pattern can be seen in the mobility dimension (3L) and, pain/discomfort and 
anxiety/depression (5L). In the NDB dataset, the mobility and usual activities dimensions for both versions of 
EQ-5D exhibit this shape 
iii. A strong mode in the centre of the distribution. 
This shape can be found in the pain/discomfort dimension in 3L in the EQG dataset and in both versions of EQ-
5D in the NDB dataset. 
iv. A mode in the centre of the distribution and an almost as large first category. 
This distributional shape is similar to shape (ii) in that they both exhibit a decreasing profile, but shape (iv) has 
less central concentration. This shape can only be found in the EQG dataset in the usual activities and 
anxiety/depression dimensions of 3L. 
 
In the NDB dataset, both versions of EQ-5D display the same pattern within each dimension but different 
shapes across dimensions: shape (i) in both the self-care and anxiety/depression dimensions, shape (ii) in the 
mobility and usual activities dimension and shape (iii) in the pain/discomfort dimension. In contrast, in the EQG 
dataset only the self-care dimension shows the same shape of distribution in both 3L and 5L. Within the EQG 
dataset, the distributional shapes for all dimensions of 5L are similar, displaying a decreasing profile 
corresponding to either shape (i) or (ii). The 3L distributions in the EQG dataset exhibit all four distributional 
shapes and appear more different across dimensions than in the 5 level version. The variation in shape highlights 
the need to use flexible model specifications which do not impose the same model structure across dimensions 
or datasets.  
 
  
Figure 2 shows kernel estimates of the distributions of utility scores in both datasets. 3L in both datasets exhibits 
the typical characteristics documented in the literature: a large mass of observations at 1 (full health), a gap of 
no observations between full health and the next feasible value (0.883) and a multimodal distribution. In both 
datasets, the distributions are smoother for 5L, especially towards the top of the distribution. The number of 
individuals in full health is reduced by using 5L and the mode at the bottom of the distribution around the value 
of zero in the -3L distribution disappears in the distribution of 5L. The mean and median of 5L are higher than 
the corresponding mean and median of 3L in both datasets (see Table 1). The range of 5L is smaller as the worst 
state has a utility score of -0.281 compared to -0.594 of 3L. 
 
Statistical model results 
The initial specification had gender, age and the square of age as covariates. The square of age was significant 
when the model was estimated with EQG data, but grossly insignificant when estimated with NDB data. The 
preferred specification for the EQG dataset has age, age squared and gender as covariates in all ten ordinal 
regressions whereas the model for the NDB dataset excludes the square of age. 
 
Table 2 summarizes the results for the two datasets. There are several differences between the models from the 
two datasets. The best fitting model in the EQG dataset chooses the same copula, Frank, in all dimensions of 
EQ-5D.  In contrast, the best fitting model in the NDB dataset selects a Gaussian copula for the mobility, usual 
activities and pain/discomfort dimensions, a Clayton copula for the self-care dimension and a Frank copula for 
the anxiety/depression dimension.  The Gaussian and Frank copulas are similar in that both allow for positive or 
negative dependence, symmetric in both tails, but the Frank form generates dependence weaker in the tails and 
stronger in the centre of the distribution. The Clayton copula allows only positive dependence, with strong left 
tail dependence and relatively weak right tail dependence; thus, if two variables are strongly correlated at low 
values but less so at high values, then the Clayton copula is a good choice. Therefore, in the EQG dataset the 
patterns of residual dependence between the 3- and 5- level versions of EQ-5D are similar across all dimensions 
indicating symmetric dependence and weak dependence on the tails. In the NDB dataset, a Frank copula was 
also selected for the anxiety/depression dimension and the parameter of dependence was very similar that 
estimated in the EQG dataset. In contrast, the Gaussian copula in the mobility, usual activities and 
pain/discomfort dimensions indicate symmetric dependence as well but stronger dependence on the tails of the 
distribution than the Frank copula selected in the EQG dataset. The copula chosen in the self-care dimension 
using the NDB dataset, the Clayton copula, displays a very different pattern of dependence compared to the 
Frank copula chosen in the EQG dataset. It exhibits asymmetric dependence on the tails with strong dependence 
at lower values and weak dependence at high values.  
 
There are significant statistical differences in the coefficients of the covariates and latent factor between 3L and 
5L in most dimensions. This is a test of the hypothesis that the underlying relationship between covariates 
and/or latent variable and EQ-5D is the same for 3L and 5L. Rejection of the hypothesis indicates  that  the 
effect of moving from 3 levels to 5 levels is not just a uniform realignment of the response levels. The only 
exception to this in both datasets is in the anxiety/depression dimension and in the self-care dimension in the 
NDB dataset. 
Cost effectiveness results 
Table 3 and Figure 3 report headline results for all the case studies. In almost all cases, the switch from 3L to 
5L, causes a decrease in the incremental QALY gain from effective health technologies. This is true whether the 
estimation of 5L is based on EQG or NDB data, with one exception.  
 
 
In COUGAR 02,  there is an increase in incremental QALYs as a result of shifting from 3L to 5L. The increase 
is small but is apparent for both versions of 5L estimates. In COUGAR 2, mortality is a very substantial driver 
of cost effectiveness. Median overall survival in the DXL + ASC group was 5.2 months (95% CI 4.1±5.9) 
versus 3.6 months (3.3±4.4) in the ASC group15. Here, the value of improved survival is greater because utility 
values are increased using 5L. It is worth noting that whilst the RAIN study also included patients with a 
substantial mortality rate (approximately 25% mortality within 6 months) this was substantially lower than in 
COUGAR-02 (approximate 6-month mortality of 75% in the control group and 60% in the docetaxel arm15) and 
did not outweigh the morbidity effect. 
 
The responses people give to the 5L instrument and the changed tariff have the combined effect of shifting mean 
utility scores further up the utility scale towards full health, and compressing them into a smaller range. Thus, 
improvements in quality of life tend to be valued less using 5L than the same clinical change  measured with 3L. 
 
In six of the nine reported comparisons, the incremental QALY gain is greater when measured using 5L and the 
EQG dataset, compared to 5L and the NDB dataset. One of the three remaining comparisons showed no 
difference. 
 
In those studies where the 5L (EQG) lowered incremental QALYs, the impact ranged from a reduction of 10.4% 
(CARDERA comparison of MTX to MTX plus PNS) to 75% (RAIN comparison of dedicated neurocritical care 
unit with combined neuro/general critical care unit). The comparable range when using mapping based on NDB 
data was 8% (CARDERA as before) to 87% (CACTUS).     
 
The impact of these changes on ICERs is also substantial in several cases. In CARDERA, the comparison of 
triple therapy compared to DMARD monotherapy changes from approximately £16k using EQ5D-3L to over 
£24k using 5L (EQG data) and over £30k using 5L (NDB data). CACTUS changes from a highly cost effective 
central estimate using 3L (£3058) to one that is more borderline (£23022) using 5L (NDB data). CVLPRIT 
changes from an ICER of just over £20k per QALY to in excess of £45k per QALY when using either estimate 
of 5L health utility. Other case studies demonstrate changes in cost effectiveness that may not span boundaries 
of typically cited cost-effectiveness thresholds but are, nevertheless, very substantial.   
 
CONCLUSIONS 
We have shown that 3L and 5L versions can produce substantially different estimates of cost effectiveness in a 
series of case studies spanning different health conditions, severities and health technologies. Technologies that 
improve quality of life have those benefits valued more highly, in terms of health utility, when using the 3L 
instrument compared to 5L. This is because of the combined effect of the changed descriptive system and how 
individuals respond to it compared to 3L (which we demonstrated is not the same across each health dimension), 
and the changed valuation system. The result is that, in almost all cases, it is estimated that the incremental cost 
effectiveness ratio of a clinically effective technology would be higher (i.e. becomes less cost-effective) if the 
5L instrument had been used in place of the 3L. Where the cost effectiveness of a technology is substantially 
driven by mortality rather than morbidity gains, the impact of shifting the 5L may lower ICERs (improve cost-
effectiveness). Consistent with our findings, a recent study that also used the EQG dataset reported that 5L leads 
to higher values overall and across all of the conditions health conditions in the EQG data23.  
 
In this sense, estimates of health gain from 3L and 5L are not consistent with each other. There is not a simple 
proportional adjustment that can be made to reconcile differences between 3L and 5L. Changes do not impact 
equally across the distribution of health and therefore different technologies are affected to a different degree by 
the shift from one instrument to another.  
 
It is feasible to adjust 3L evidence to its 5L equivalent, as has been done in this paper. The validity of this 
approach is, in part, dependent on the data on which it is based. We have demonstrated this method in two 
separate datasets and shown that they give substantially different results. Further investigation of the reasons for 
these differences is required. In particular, the NDB includes only patients with rheumatoid disease and may not 
be generalizable to other populations. However, the design of the NDB questionnaires included much more 
separation between the completion of 3L and 5L and may, therefore, offer observations given without recall of 
previous responses than the EQG studies. The NDB is also predominantly conducted in the English language. 
Whilst there is some evidence that the ranking of levels 4 DQG³VHYHUH´DQG³H[WUHPH´SUREOHPVPD\QRWEH
as expected in the English valuation study8, this is less likely to be an issue affecting the descriptive system 
when respondents are provided with all five levels in their expected order.  Therefore, we do not feel there is a 
rationale to prefer English speaking samples for the mapping work.  Both datasets are also limited by their size 
and coverage of relevant health states. In the EQG data, only 119 of the possible 233 EQ-5D-3L utility values 
are observed.  That figure is 83 for the NDB. We know that most of the 233 health states do appear in real 
patient records. For example, in UK 2010-2014 data for knee replacement procedures (n=320,000) we find 189 
out of 233 possible utility values. There is a pressing need for well designed, large scale data collection to 
extend this work.  
 
There are a number of implications for policy in the light of these results. Given the differences between 3L and 
5L consistency in decision making will be difficult to achieve. Consideration must be given to the value of any 
cost-effectiveness threshold (or thresholds) or other means for making adjustments between the two instruments. 
Mapping can help achieve this, and the copula-EDVHGPHWKRGLVDVRSKLVWLFDWHGGHYHORSPHQWRI³UHVSRQVH-
PDSSLQJ´WKDWREWDLQVFRQVLVWHQWDQGDFFXUDWHUHVXOWVA single approach to mapping between 3L and 5L would 
aid consistent decision making. Additional data collection would also permit extended validation of the method 
DQGFRPSDULVRQDJDLQVWWKH(XUR4R/³FURVVZDON´WKDWSURYLGHVDOLQNEHWZHHQ/UHVSRQVHVDQG/24.  Decision 
making bodies, like NICE in the UK, should endorse the use of either 3L or 5L and a set of methods that allow 
evidence to be linked from one to the other. 5L is increasingly being used in studies of clinical effectiveness, but 
this is unlikely to entirely replace existing evidence using 3L that will remain of relevance to many economic 
evaluations for many years to come.  
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TABLES:  
Table 1: Descriptive statistics in the EQG and NDB estimation samples 
 EQG sample NDB sample 
AGE   
Mean  
[95%  confidence Interval] 
51.23 
[50.57, 51.89] 
63.32 
[62.99, 63.65] 
Median 
[95%  confidence Interval] 
54 
[54, 56] 
64.13 
[63.78, 64.46] 
Standard Deviation 20.11 12.31 
Minimum 13 16.66 
Maximum 99 95.20 
   
Proportion female 0.53 0.81 
 EQ-5D-3L EQ-5D-5L EQ-5D-3L EQ-5D-5L 
UTILITY     
Mean 
[95%  confidence Interval] 
0.628 
[0.617, 0.639] 
0.712 
[0.703, 0.722] 
0.681 
[0.674, 0.688] 
0.779 
[0.773, 0.784] 
Median 
[95%  confidence Interval] 
0.691 
[0.691, 0.725] 
0.802 
[0.792, 0.816] 
0.725 
[0.725, 0.727] 
0.823 
[0.817, 0.829] 
Standard Deviation 0.333 0.278 0.254 0.191 
Minimum -0.594 -0.281 -.594 -0.226 
Maximum 1 1 1 1 
     
Number of health states 
[percentage out of possible 
health states] 
123 
[50.62] 
660 
[21.12] 
86 
[35.39] 
524 
[16.77] 
 
Table 2: Summary of final model results 
 EQG NDB 
Log-likelihood -23891.83 -33621.04 
Number of parameters 78 68 
Observations 3551 5205 
Type of mixture in copula Single mixture Single mixture 
Dimension Specific   
Mobility   
Copula Frank Gaussian 
Equality of coefficients (covariates) 7.12* 11.86*** 
Equality of coefficients (latent factor) 8.37*** 10.64*** 
Equality of coefficients (covariates & factor) 12.19** 26.49*** 
Self-care   
Copula Frank Clayton 
Equality of coefficients (covariates) 8.53** 1.21 
Equality of coefficients (latent factor) 3.68* 0.09 
Equality of coefficients (covariates & factor) 9.39* 1.35 
Usual activities   
Copula Frank Gaussian 
Equality of coefficients (covariates) 3.29 0.67 
Equality of coefficients (latent factor) 5.62** 8.24*** 
Equality of coefficients (covariates & factor) 0.04** 9.11** 
Pain/discomfort   
Copula Frank Gaussian 
Equality of coefficients (covariates) 0.57 34.36*** 
Equality of coefficients (latent factor) 9.36*** 19.99*** 
Equality of coefficients (covariates & factor) 11.95** 50.74*** 
Anxiety/depression   
Copula Frank Frank 
Equality of coefficients (covariates) 5.60 4.94* 
Equality of coefficients (latent factor) 1.23 1.94 
Equality of coefficients (covariates & factor) 7.08 6.19 
Statistical significance: * = 10%, ** = 5%, *** = 1% 
 
Table 3: Incremental QALYs and ICERs for 3L, 5L (EQG) and 5L (NDB) across all case studies 
 
Inc QALYs ICER 
 
3L 5L EQG % change 5L NDB % change 3L 5L EQG % change 5L NDB % change 
CARDERA 1 0.145 0.113 -21.8% 0.111 -23.2% 4648 5940 27.8% 6054 30.3% 
CARDERA 2  0.084 0.075 -10.4% 0.077 -8.0% 13666 15252 11.6% 14846 8.6% 
CARDERA 3  0.082 0.054 -33.5% 0.043 -47.6% 15929 23940 50.3% 30418 91.0% 
Cactus 0.150 0.050 -66.7% 0.020 -86.7% 3058 9481 210.0% 23022 652.8% 
Rain a 0.020 0.005 -75.0% 0.003 -85.0% 184700 738800 300.0% 1231333 566.7% 
Rain b 0.051 0.021 -58.8% 0.021 -58.8% 294137 714333 142.9% 714333 142.9% 
Improve 0.052 0.046 -11.5% 0.042 -19.2% -44617* -48113 7.8% -54742 22.7% 
Cougar 2 0.115 0.119 3.5% 0.118 2.6% 27180 26434 -2.7% 26484 -2.6% 
Arctic 0.059 0.043 -27.1% 0.046 -22.0% 112193 162774 45.1% 152130 35.6% 
Sharpish 0.000 -0.003  NA  -0.003 NA   NA**         
WRAP - CP12 0.062 0.047 -23.7% 0.039 -36.2% 1812 2373 31.0% 2840 56.7% 
WRAP - CP52 0.044 0.044 0.0% 0.036 -19.0% 4305 4312 0.2% 5316 23.5% 
CvLPRIT 0.020 0.010 -52.5% 0.009 -53.0% 21496 46761 117.5% 47521 121.1% 
CARDERA 1 = MTX vs MTX + CS, CARDERA 2 = MTX vs MTX + PNS, CARDERA 3 = MTX + CS + PNS vs MTX 
* In the IMPROVE study, the technology of interest (endovascular aneurysm repair) was cost saving.  
** Incremental QALYs near zero meant the calculation of the ICER may be misleading and was therefore not reported.  
 
 
 FIGURES 
Figure 1: Response histograms for EQ-5D-3L and EQ-5D-5L in the EQG dataset and the NDB dataset 
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Figure 2: Smoothed empirical distribution functions of EQ-5D-3L and EQ-5D-5L in the EQG and NDB 
datasets. 
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Figure 3: Histogram of incremental QALYs by 3L, 5L (EQG) and 5L (NDB) for all case studies 
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